Treatment paradigms with epidermal growth factor receptor-targeted therapies in colorectal cancer

Area of Science:

• Oncology
• Gastroenterology
• Pharmacology

Background:

• Epidermal growth factor receptor (EGFR) is a validated target for metastatic colorectal cancer (mCRC).
• Initial research focused on EGFR inhibitors for chemotherapy-refractory mCRC.
• Emerging trends include KRAS mutation status for patient selection and earlier therapy initiation.

Purpose of the Study:

• To review the use of EGFR-targeted monoclonal antibodies (cetuximab and panitumumab) in mCRC.
• To discuss the incorporation of KRAS testing in patient selection for anti-EGFR therapy.
• To review prophylactic strategies for skin toxicity associated with EGFR-targeted therapies.

Main Methods:

• Literature review of studies on EGFR inhibitors in mCRC.
• Analysis of the role of KRAS mutation status in treatment selection.
• Review of data on skin toxicity management for EGFR-targeted therapies.

Main Results:

• KRAS mutation status is crucial for identifying mCRC patients who benefit from anti-EGFR therapy.
• EGFR inhibitors are increasingly used in earlier lines of therapy for mCRC.
• Prophylactic measures can mitigate skin toxicity, improving patient adherence and outcomes.

Conclusions:

• KRAS testing is essential for optimizing anti-EGFR therapy in mCRC.
• The strategic use of EGFR inhibitors in earlier treatment phases holds significant promise.
• Managing side effects like skin toxicity is vital for successful EGFR-targeted treatment in mCRC.